|
Lupus Erythematosus, Systemic
|
0.550 |
Biomarker
|
disease |
MGD |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The human PRDI-BF1 or BLIMP1 gene and its mouse homolog Blimp1 are members of the recently realized PR domain family that includes the retinoblastoma interacting zinc finger gene RIZ and the MDS1-EVI1 leukemia cancer gene.
|
8921366 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data led us to suggest that BLIMP1 may be a candidate B-NHL tumor suppressor gene.
|
8921366 |
1996 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The data led us to suggest that BLIMP1 may be a candidate B-NHL tumor suppressor gene.
|
8921366 |
1996 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
The human PRDI-BF1 or BLIMP1 gene and its mouse homolog Blimp1 are members of the recently realized PR domain family that includes the retinoblastoma interacting zinc finger gene RIZ and the MDS1-EVI1 leukemia cancer gene.
|
8921366 |
1996 |
|
Retinoblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The human PRDI-BF1 or BLIMP1 gene and its mouse homolog Blimp1 are members of the recently realized PR domain family that includes the retinoblastoma interacting zinc finger gene RIZ and the MDS1-EVI1 leukemia cancer gene.
|
8921366 |
1996 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human PRDI-BF1 or BLIMP1 gene and its mouse homolog Blimp1 are members of the recently realized PR domain family that includes the retinoblastoma interacting zinc finger gene RIZ and the MDS1-EVI1 leukemia cancer gene.
|
8921366 |
1996 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human PRDI-BF1 or BLIMP1 gene and its mouse homolog Blimp1 are members of the recently realized PR domain family that includes the retinoblastoma interacting zinc finger gene RIZ and the MDS1-EVI1 leukemia cancer gene.
|
8921366 |
1996 |
|
Lymphoma
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Blimp-1 in B lymphoma cells has been reported to induce either growth arrest and cell death or Ig secretion and terminal differentiation, depending on the developmental stage of the recipient lymphomas.
|
10508273 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two alternative products of the gene exist, RIZ1, which contains a PR (PRDI-BF1-RIZ1) domain implicated in tumor suppressor function, and RIZ2, which is lacking this motif.
|
10688904 |
2000 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.
|
12165517 |
2002 |
|
Multiple Myeloma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that premature Blimp-1 expression coupled to altered and deficient Pax5 expression causes some proliferating B cells to prematurely differentiate to plasma cells in MM.
|
12453881 |
2002 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we show that four of these genes (guanine nucleotide binding protein gamma 3; mitochondrial carrier homolog 2; p53-induced protein (PIG11), and pRDI-BF1-rIZ1 domain containing 11) localized to the minimal liver tumor suppressor region within 11p11.2-p12.
|
12557265 |
2003 |
|
Retinoblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Among them, MEL1S, an alternatively spliced form of MEL1 lacking the PR (positive regulatory domain I binding factor 1 and retinoblastoma-interacting zinc finger protein) domain, was frequently transcribed in ATL cells, and the transcriptional initiation sites were identified upstream from exons 4 and 6.
|
14656887 |
2004 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A minority of diffuse large B-cell lymphomas expressed PRDM1 and Hodgkin lymphomas were largely PRDM1-.
|
15772984 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, a mouse monoclonal antibody that recognizes PRDM1 was used to detail its distribution in normal human lymphoid tissue and in lymphoid neoplasms that correspond to different stages of B-cell differentiation.
|
15772984 |
2005 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Infiltrating T-cells in PRDM1- B-cell lymphomas expressed PRDM1.
|
15772984 |
2005 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
A minority of diffuse large B-cell lymphomas expressed PRDM1 and Hodgkin lymphomas were largely PRDM1-.
|
15772984 |
2005 |
|
Multiple Myeloma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
|
16002735 |
2005 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study identifies PRDM1 inactivation as a recurrent genetic defect in DLBCL cells and establishes PRDM1 as a potential tumor suppressor gene in DLBCL.
|
16424392 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study identifies PRDM1 inactivation as a recurrent genetic defect in DLBCL cells and establishes PRDM1 as a potential tumor suppressor gene in DLBCL.
|
16424392 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas.
|
16424392 |
2006 |
|
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report here that the BLIMP1 gene is inactivated by structural alterations in 24% (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-like (n = 0/37) or unclassified (n = 0/21) DLBCL.
|
16492805 |
2006 |